Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction

INTRODUCTION: High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic class. Higher doses of mesalazine may be required during periods of remission...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Haens, Geert, Safroneeva, Ekaterina, Thorne, Helen, Laoun, Raphaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601940/
https://www.ncbi.nlm.nih.gov/pubmed/37901343
http://dx.doi.org/10.1159/000531372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601940/
https://www.ncbi.nlm.nih.gov/pubmed/37901343
http://dx.doi.org/10.1159/000531372

Ejemplares similares